Jazz Pharmaceuticals PLC
JAZZ: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $228.00 | Ftf | Tyznqjj |
Jazz Pharmaceuticals Reports in Line Q4 Results; Maintaining $187 FVE, Shares Undervalued
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
Jazz Pharmaceuticals reported solid fourth-quarter results and ended 2022 with total revenue of $3.7 billion, representing an 18% increase over 2021. Continued strong performance from Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have been Jazz’s primary growth drivers. We maintain our fair value estimate of $187 per share, and we believe shares are currently trading at an attractive entry point, about 21% below our fair value estimate.